GlassScriptEnroute Transcarotid Stent
Payments companies reported to CMS as associated with Enroute Transcarotid Stent. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Enroute Transcarotid Stent, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Enroute Transcarotid Stent
These are the largest totals companies reported as associated with Enroute Transcarotid Stent. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Peter Schneider | Honolulu, HI | Vascular Surgery | $749,767.14 |
| Douglas Massop | West Des Moines, IA | Vascular Surgery | $314,540.75 |
| Mariano Arosemena | Bradenton, FL | Vascular Surgery | $258,620.99 |
| Enrique Criado Pallares | Midland, MI | Vascular Surgery | $240,000.00 |
| Trevor Derderian | Rancho Mirage, CA | Vascular Surgery | $144,926.30 |
| Jeffrey Jim | Saint Louis, MO | Vascular Surgery | $138,649.00 |
| Rasesh Shah | Chesapeake, VA | Vascular Surgery | $108,889.93 |
| Brian Peterson | Saint Louis, MO | Vascular Surgery | $105,392.36 |
| Siddharth Patel | Atlanta, GA | Vascular Surgery | $100,923.28 |
| Nathan Aranson | S Portland, ME | Vascular Surgery | $91,526.79 |
Prescribed Enroute Transcarotid Stent?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.